Skip to main content
SpringerLink
Log in

Tigecycline

A Viewpoint by Ethan Rubinstein

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005 Aug; 5(8): 501–13

    Article  PubMed  Google Scholar 

  2. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004 Oct 1; 39(7): 885–910

    Article  PubMed  Google Scholar 

  3. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005 Jun 15; 40(12): 1785–91

    Article  PubMed  Google Scholar 

  4. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of 2 double-blind phase 3 comparisons studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl. 5: S341–53

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Manitoba Faculty of Medicine, Winnipeg, Manitoba, Canada

    Ethan Rubinstein

Authors
  1. Ethan Rubinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubinstein, E. Tigecycline. Drugs 65, 2636 (2005). https://doi.org/10.2165/00003495-200565180-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565180-00009

Keywords

Search

Navigation